Post Marketing Study on Pluvicto in Korea
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Post marketing study on Pluvicto in Korea
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent jest mężczyzną w wieku 18 lat lub starszym.
- •Pacjent jest leczony lekiem Pluvicto lub ma zaplanowane leczenie tym lekiem zgodnie z zatwierdzonym wskazaniem w Korei Południowej.
- •Pacjent wyraził pisemną zgodę na udział w badaniu przed jego rozpoczęciem.
✗ Disqualifies
- •Nie można uzyskać dostępu do dokumentacji medycznej pacjenta.
- •Pacjent nie chce wyrazić zgody na udział w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 6, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (12)
Novartis Investigative Site
Seongnam-si, South Korea
Novartis Investigative Site
Suwon, South Korea
Novartis Investigative Site
Busan, South Korea
Novartis Investigative Site
Gyeonggi-do, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Jeollanam, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.